Advanced

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma

Bex, Axel; Albiges, Laurence; Ljungberg, Börje; Bensalah, Karim; Dabestani, Saeed LU ; Giles, Rachel H.; Hofmann, Fabian; Hora, Milan; Kuczyk, Markus A. and Lam, Thomas B., et al. (2018) In European Urology 74(6). p.805-809
Abstract

Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic clear-cell renal cancer who present with the tumour in place. The CARMENA trial compared systemic therapy alone with CN followed by systemic therapy. This article outlines the new guidelines based on these data. Patient summary: The CARMENA trial demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in patients diagnosed with intermediate and poor risk metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden poor risk patients experience hearing that removal of their primary tumour will not be beneficial, should be carefully considered. CARMENA... (More)

Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic clear-cell renal cancer who present with the tumour in place. The CARMENA trial compared systemic therapy alone with CN followed by systemic therapy. This article outlines the new guidelines based on these data. Patient summary: The CARMENA trial demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in patients diagnosed with intermediate and poor risk metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden poor risk patients experience hearing that removal of their primary tumour will not be beneficial, should be carefully considered. CARMENA demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in intermediate- and poor-risk patients with metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden that poor-risk patients experience on hearing that removal of their primary tumour will not be beneficial should be carefully considered. The renal cell carcinoma guidelines panel has revisited their treatment recommendations for Memorial Sloan Kettering Cancer Center intermediate- and poor-risk patients.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cytoreductive nephrectomy, EAU guidelines, Metastatic, Renal cell cancer, Sunitinib
in
European Urology
volume
74
issue
6
pages
805 - 809
publisher
Elsevier
external identifiers
  • scopus:85054059866
ISSN
0302-2838
DOI
10.1016/j.eururo.2018.08.008
language
English
LU publication?
yes
id
2cf14703-455f-4330-848a-2022f03dfca5
date added to LUP
2018-10-23 13:48:28
date last changed
2019-01-14 17:11:26
@misc{2cf14703-455f-4330-848a-2022f03dfca5,
  abstract     = {<p>Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic clear-cell renal cancer who present with the tumour in place. The CARMENA trial compared systemic therapy alone with CN followed by systemic therapy. This article outlines the new guidelines based on these data. Patient summary: The CARMENA trial demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in patients diagnosed with intermediate and poor risk metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden poor risk patients experience hearing that removal of their primary tumour will not be beneficial, should be carefully considered. CARMENA demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in intermediate- and poor-risk patients with metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden that poor-risk patients experience on hearing that removal of their primary tumour will not be beneficial should be carefully considered. The renal cell carcinoma guidelines panel has revisited their treatment recommendations for Memorial Sloan Kettering Cancer Center intermediate- and poor-risk patients.</p>},
  author       = {Bex, Axel and Albiges, Laurence and Ljungberg, Börje and Bensalah, Karim and Dabestani, Saeed and Giles, Rachel H. and Hofmann, Fabian and Hora, Milan and Kuczyk, Markus A. and Lam, Thomas B. and Marconi, Lorenzo and Merseburger, Axel S. and Fernández-Pello, Sergio and Tahbaz, Rana and Abu-Ghanem, Yasmin and Staehler, Michael and Volpe, Alessandro and Powles, Thomas},
  issn         = {0302-2838},
  keyword      = {Cytoreductive nephrectomy,EAU guidelines,Metastatic,Renal cell cancer,Sunitinib},
  language     = {eng},
  month        = {08},
  number       = {6},
  pages        = {805--809},
  publisher    = {Elsevier},
  series       = {European Urology},
  title        = {Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma},
  url          = {http://dx.doi.org/10.1016/j.eururo.2018.08.008},
  volume       = {74},
  year         = {2018},
}